Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial.
Saved in:
| Title: | Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial. |
|---|---|
| Authors: | Hysa A; Burnet Institute, Melbourne, Australia.; Department of Infectious Diseases and Department of Medicine, The University of Melbourne, Melbourne, Australia., Opi DH; Burnet Institute, Melbourne, Australia.; Department of Infectious Diseases and Department of Medicine, The University of Melbourne, Melbourne, Australia.; School of Translational Medicine and Department of Microbiology, Monash University, Melbourne, Australia., Waterhouse J; Burnet Institute, Melbourne, Australia.; School of Translational Medicine and Department of Microbiology, Monash University, Melbourne, Australia., Chishimba S; Burnet Institute, Melbourne, Australia.; Department of Infectious Diseases and Department of Medicine, The University of Melbourne, Melbourne, Australia., Horton JL; Burnet Institute, Melbourne, Australia.; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, England, United Kingdom., Kingston N; Astbury Centre for Structural Molecular Biology, School of Molecular & Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom., Netter HJ; School of Science, RMIT University, Melbourne, Australia., Wetzel D; ARTES Biotechnology GmbH, Langenfeld, Germany., Piontek M; ARTES Biotechnology GmbH, Langenfeld, Germany.; Laboratory of Plant and Process Design, Technical University of Dortmund, Dortmund, Germany., Feng G; Burnet Institute, Melbourne, Australia.; National Vaccine Innovation Platform, NHC Key Laboratory of Antibody Technique, Jiangsu Key Laboratory of Pathogen Biology, Department of Pathogen Biology, Nanjing Medical University, Nanjing, Jiangsu, China., Sacarlal J; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.; Faculdade de Medicina, Universidade Eduardo Mondlane (UEM), Maputo, Mozambique., Dobaño C; ISGlobal, Hospital Clínic Universitat de Barcelona, Barcelona, Catalonia, Spain.; SGlobal, Hospital Clínic Universitat de Barcelona, and Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Barcelona, Spain., Kurtovic L; Burnet Institute, Melbourne, Australia.; Department of Infectious Diseases and Department of Medicine, The University of Melbourne, Melbourne, Australia.; School of Translational Medicine and Department of Microbiology, Monash University, Melbourne, Australia., Beeson JG; Burnet Institute, Melbourne, Australia.; Department of Infectious Diseases and Department of Medicine, The University of Melbourne, Melbourne, Australia.; School of Translational Medicine and Department of Microbiology, Monash University, Melbourne, Australia. |
| Source: | PLoS medicine [PLoS Med] 2026 May 14; Vol. 23 (5), pp. e1004877. Date of Electronic Publication: 2026 May 14 (Print Publication: 2026). |
| Publication Type: | Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II |
| Journal Info: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1549-1676 |
|---|---|
| DOI: | 10.1371/journal.pmed.1004877 |
